Today, a Director at Integra Lifesciences (IART), Raymond Murphy, sold shares of IART for $252.2K.
Following Raymond Murphy’s last IART Sell transaction on March 06, 2017, the stock climbed by 19.2%. In addition to Raymond Murphy, 3 other IART executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Integra Lifesciences’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $384 million and quarterly net profit of $29.74 million. In comparison, last year the company earned revenue of $366 million and had a net profit of $11.38 million. The company has a one-year high of $66.41 and a one-year low of $42.14. Currently, Integra Lifesciences has an average volume of 460.76K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy IART with a $69 price target.
The insider sentiment on Integra Lifesciences has been negative according to 67 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Raymond Murphy’s trades have generated a -20.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments.
